One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1136/annrheumdis-2017-eular.1420
Copy DOI Journal: Annals of the Rheumatic Diseases |  Publication Date: Jun 1, 2017 |
 Citations: 2 |
Affiliation: Institute for Rheumatic Diseases (Japan), Pfizer (Japan), Daido University, Hokkaido University, The University of Tokyo, Kagoshima University, Nippon Medical School, Kishokai Medical Corporation, Kyoto University, Juntendo University, Wakayama Medical University, Tokyo Women's Medical UniversityBackgroundTofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in RA patients in global Phase 2, Phase 3...
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
